Table F-85-year relative survival by age and race for breast cancer

Race and AgePercent Surviving at End of Interval
White
AgeNumber at Start of Followup1 year2 years3 years4 years5 years
0-4411,15599.00%96.40%94.10%91.90%89.60%
45-4521,05399.00%97.20%95.20%93.60%92.20%
55-6421,81498.30%96.70%95.00%93.40%91.90%
65-7416,93398.10%96.90%95.10%93.40%92.20%
75+18,5740.10%0.20%0.30%0.30%0.40%
Black
Age
0-44209096.40%94.40%92.90%91.90%90.50%
45-45294396.70%90.00%83.90%79.70%75.90%
55-64247696.60%90.20%85.10%81.10%77.90%
65-74159995.50%91.00%87.00%82.60%79.60%
75+141188.40%83.80%80.10%74.50%72.30%

From: Appendix F, Model Description and Parameters

Cover of Oral Contraceptive Use for the Primary Prevention of Ovarian Cancer
Oral Contraceptive Use for the Primary Prevention of Ovarian Cancer.
Evidence Reports/Technology Assessments, No. 212.
Havrilesky LJ, Gierisch JM, Moorman PG, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.